PAUL HOPPER – NON EXECUTIVE CHAIRMAN
Paul Hopper has international and ASX biotech capital markets experience and over 25 years’ experience in the medical, healthcare & life sciences sectors, particularly in immune-oncology and vaccines. He is the former Chairman of Viralytics Ltd (acquired by Merck for $500m in 2018), Founder and Director of Prescient Therapeutics Ltd, Founder of Imugene Ltd and Polynoma LLC, former Director of pSivida Corp, Somnomed Ltd and Fibrocell Science, Inc. Paul has deep experience in corporate governance, risk and strategy.
STEPHEN CARTER – MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER
Stephen Carter joined the company in October 2010 as Chief Executive Officer and Managing Director. He has over 30 years pharmaceutical industry experience and has held a variety of senior positions with publicly listed companies including roles as both Chairman and Managing Director. Amongst his previous roles, Stephen was Chairman of Hollista Colltech Ltd and DelMedica Ltd; and he was Managing Director of ASX-listed Solbec Pharmaceuticals Ltd. He has extensive contacts and experience in the financial markets and the pharmaceutical industry and is well equipped to lead executive management through the company’s product commercialisation phase.
DAVID PHILLIPS – EXECUTIVE DIRECTOR
David Phillips joined the Board as a Non-Executive Director in April 2018. He has 30 years of experience in the global healthcare industry, including Glaxo Wellcome, Cephalon Inc, Oxford Molecular Group Plc and SR One (GlaxoSmithKline’s corporate venture fund). David spent 12 years at Board level as Chief Business Officer of Argenta Discovery, The Automation Partnership and BioFocus PLC. David re-joined GlaxoSmithKline’s (GSK) SR One corporate venture arm in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and in parallel investing in early-stage life science companies. David leads the Business Development activities.
DAVID SIMMONDS – NON-EXECUTIVE DIRECTOR
David was a senior audit partner with Ernst & Young from 1989 to 2017. From 2008 to 2013, David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. As an audit partner, David was involved in several high-profile businesses including Ramsay Health Care Ltd, John Fairfax Holdings and Commonwealth Bank of Australia and also was audit partner for the Australian operations of the leading US technology companies Hewlett Packard, Sun Microsystems and Oracle. David is currently a member of the Board and chairs the Audit, Risk and Finance Committee of MS Research Australia, the largest national not-for-profit body dedicated to funding and coordinating multiple sclerosis research in Australia